Chemistry:Tiagabine

From HandWiki
Short description: Anticonvulsant medication
Tiagabine
Tiagabine.svg
Clinical data
Pronunciation/taɪˈæɡəbiːn/
Trade namesGabitril
AHFS/Drugs.comMonograph
MedlinePlusa698014
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration		Oral (tablets)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability90–95%[1]
Protein binding96%[1]
MetabolismHepatic (CYP450 system,[1] primarily CYP3A)[2]
Onset of actionTmax = 45 min[2]
Elimination half-life5–8 hours[3]
ExcretionFecal (63%) and renal (25%)[2]
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
Chemical and physical data
FormulaC20H25NO2S2
Molar mass375.55 g·mol−1
3D model (JSmol)
  (verify)

Tiagabine (trade name Gabitril) is an anticonvulsant medication produced by Cephalon that is used in the treatment of epilepsy. The drug is also used off-label in the treatment of anxiety disorders and panic disorder.

Medical uses

Tiagabine is approved by U.S. Food and Drug Administration (FDA) as an adjunctive treatment for partial seizures in individuals of age 12 and up. It may also be prescribed off-label by physicians to treat anxiety disorders and panic disorder as well as neuropathic pain (including fibromyalgia). For anxiety and neuropathic pain, tiagabine is used primarily to augment other treatments. Tiagabine may be used alongside selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, or benzodiazepines for anxiety, or antidepressants, gabapentin, other anticonvulsants, or opioids for neuropathic pain.[4] It is effective as monotherapy and combination therapy with other antiepileptic drugs in the treatment of partial seizure.[5]

The American Academy of Sleep Medicine's 2017 clinical practice guidelines recommended against the use of tiagabine in the treatment of insomnia due to poor effectiveness and very low quality of evidence.[6]

Side effects

Side effects of tiagabine are dose related.[5] The most common side effect of tiagabine is dizziness.[7] Other side effects that have been observed with a rate of statistical significance relative to placebo include asthenia, somnolence, nervousness, memory impairment, tremor, headache, diarrhea, and depression.[7][8] Adverse effects such as confusion, aphasia (difficulty speaking clearly)/stuttering, and paresthesia (a tingling sensation in the body's extremities, particularly the hands and fingers) may occur at higher dosages of the drug (e.g., over 8 mg/day).[7] Tiagabine may induce seizures in those without epilepsy, particularly if they are taking another drug which lowers the seizure threshold.[4] There may be an increased risk of psychosis with tiagabine treatment, although data is mixed and inconclusive.[1][9] Tiagabine can also reportedly interfere with visual color perception.[1]

Warning

  • CNS depression
  • Dermatologic reactions
  • Generalized weakness
  • Ophthalmic effects
  • Suicidal ideation[10]

Overdose

Tiagabine overdose can produce neurological symptoms such as lethargy, single or multiple seizures, status epilepticus, coma, confusion, agitation, tremors, dizziness, dystonias/abnormal posturing, and hallucinations, as well as respiratory depression, tachycardia, hypertension, and hypotension.[11] Overdose may be fatal especially if the victim presents with severe respiratory depression and/or unresponsiveness.[11]

Pharmacology

Tiagabine increases the level of γ-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system, by blocking the GABA transporter 1 (GAT-1), and hence is classified as a GABA reuptake inhibitor (GRI).[3][12]

Pharmacodynamics

Tiagabine is primarily used as an anticonvulsant in the treatment of epilepsy as a supplement. Although the exact mechanism by which Tiagabine exerts its antiseizure effect is unknown, it is thought to be related to its ability to increase the activity of gamma aminobutyric acid (GABA), the central nervous system's major inhibitory neurotransmitter. Tiagabine attaches to the GABA uptake carrier's recognition sites. Tiagabine is thought to block GABA uptake into presynaptic neurons as a result of this action, allowing more GABA to be available for receptor binding on the surfaces of post-synaptic cells.[13]

Effects on cortical delta oscillations

Tiagabine enhances the power of cortical delta (< 4 Hz) oscillations up to 1000% relative to placebo, which may result in an EEG or MEG signature resembling non-rapid eye movement sleep even while the person who has taken tiagabine is awake and conscious.[14] This demonstrates that cortical delta activity and wakeful consciousness are not mutually exclusive, i.e., high amplitude delta oscillations are not always a reliable indicator of unconsciousness.

Tiagabine (15 mg) enhances MEG delta power in healthy volunteers.

Monitoring Parameters

Seizure frequency, liver function tests, suicidality[15]

History

Tiagabine was discovered at Novo Nordisk in Denmark in 1988 by a team of medicinal chemists and pharmacologists under the general direction of Claus Bræstrup.[16] The drug was co-developed with Abbott Laboratories, in a 40/60 cost sharing deal, with Abbott paying a premium for licensing the IP from the Danish company.[citation needed]

U.S. patents on tiagabine listed in the Orange Book expired in April 2016.[17]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "Antiseizure Drugs". Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. 24 January 2012. pp. 562–. ISBN 978-1-60913-345-0. https://books.google.com/books?id=Sd6ot9ul-bUC&pg=PA562. 
  2. ↑ 2.0 2.1 2.2 "Gabitril (tiagabine hydrochloride) Tablets. U.S. Full Prescribing Information". Cephalon, Inc.. http://www.gabitril.com/Gabitril_PI.pdf. 
  3. ↑ 3.0 3.1 "Tiagabine pharmacology in profile". Epilepsia 36 (Suppl 6): S7–S9. 1995. doi:10.1111/j.1528-1157.1995.tb06015.x. PMID 8595791. 
  4. ↑ 4.0 4.1 Stahl's essential psychopharmacology: the prescriber's guide; antipsychotics and mood stabilizers (3rd ed.). New York, NY: Cambridge University Press. 2009. pp. 523–526. ISBN 978-0-521-75900-7. 
  5. ↑ 5.0 5.1 "Tiagabine", LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases), 2012, PMID 31643697, http://www.ncbi.nlm.nih.gov/books/NBK548376/, retrieved 2021-12-24 
  6. ↑ "Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline". Journal of Clinical Sleep Medicine 13 (2): 307–349. February 2017. doi:10.5664/jcsm.6470. PMID 27998379. 
  7. ↑ 7.0 7.1 7.2 "Tiagabine: the safety landscape". Epilepsia 36 (Suppl 6): S10–S13. 1995. doi:10.1111/j.1528-1157.1995.tb06009.x. PMID 8595787. 
  8. ↑ Antiepileptic Drugs: Pharmacology and Therapeutics. Springer Science & Business Media. 6 December 2012. pp. 459–. ISBN 978-3-642-60072-2. https://books.google.com/books?id=8iv6CAAAQBAJ&pg=PA459. 
  9. ↑ "Antihistamines". Meyler's Side Effects of Psychiatric Drugs. Elsevier. 2009. pp. 652–. ISBN 978-0-444-53266-4. https://books.google.com/books?id=AmYFTSO8jCkC&pg=PA652. 
  10. ↑ "Tiagabine (gabitril) experience in children". Epilepsia 42 (Suppl 3): 49–51. 2001-12-20. doi:10.1046/j.1528-1157.2001.042suppl.3049.x. PMID 11520324. 
  11. ↑ 11.0 11.1 "Retrospective evaluation of tiagabine overdose". Clinical Toxicology 43 (7): 855–859. 2009. doi:10.1080/15563650500357529. PMID 16440513. 
  12. ↑ "The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study". The Journal of Clinical Psychiatry 66 (11): 1401–1408. November 2005. doi:10.4088/JCP.v66n1109. PMID 16420077. 
  13. ↑ "Gabitril (tiagabine) dosing, indications, interactions, adverse effects, and more". https://reference.medscape.com/drug/gabitril-tiagabine-343022#91. 
  14. ↑ "Paradoxical pharmacological dissociations result from drugs that enhance delta oscillations but preserve consciousness". Communications Biology 6 (1): 654. June 2023. doi:10.1038/s42003-023-04988-8. PMID 37340024. 
  15. ↑ "Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy". Drugs 55 (3): 437–460. March 1998. doi:10.2165/00003495-199855030-00013. PMID 9530548. 
  16. ↑ "The synthesis of novel GABA uptake inhibitors. 1. Elucidation of the structure-activity studies leading to the choice of (R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic acid (tiagabine) as an anticonvulsant drug candidate". Journal of Medicinal Chemistry 36 (12): 1716–1725. June 1993. doi:10.1021/jm00064a005. PMID 8510100. 
  17. ↑ "Search Results for Tiagabine". Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=020646&TABLE1=OB_Rx. 

External links



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Tiagabine&oldid=3711398"